Skip to content
Friday 7 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,928.99
+0.56%
DAX
26,343.29
+0.78%
CAC 40
8,729.87
+0.35%
STOXX 50
6,541.84
+0.60%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Monday 28 July 2008 10:10 am  |  Updated:  Thursday 11 November 2021 10:19 am

Apple boss does not have repeat cancer

By: David Crow

Add as a preferred source on Google

Apple’s chief executive Steve Jobs, who has been dogged by speculation over his health, does not have recurrent cancer or another terminal illness


According to a source close to Apple, rumours that Jobs is suffering from cancer are over-exaggerated. The source said it was common for those recovering from pancreatic cancer to experience weight loss, due to complications with intestinal surgery.

In 2004, Jobs, currently 53, announced he had undergone successful intestinal surgery to remove a rare type of pancreatic cancer. But Apple’s decision to keep the illness a secret until he was given the all-clear has left investors suspicious.

During a keynote speech at last month’s World Wide Developer conference, it was clear that Jobs had lost a substantial amount of weight and was unable to hold the floor for as long as usual. He took regular breaks, allowing guest speakers to fill the gaps.

Apple immediately denied that Jobs was seriously unwell, saying that antibiotics for a common bug had led him to lose weight. But the reasons Apple offered for Jobs’ tired and gaunt appearance failed to convince investors.

The concerns over his illness resurfaced last week when Apple released its third quarter results. Despite announcing record profits, the firm warned that full-year revenues would be $500m lower than Wall Street expectations.

Coupled with Apple’s pointed refusal to discuss Jobs’ health, which it says is a private matter, the warning unnerved investors, sending the stock falling by ten per cent.

Many investors see Jobs’ leadership as inextricable from Apple’s successes in the last decade. Since his return to the company in 1996, he has overseen the launch of its most successful products, including the iMac, iPod, iTunes and iPhone.

Before he re-joined Apple, having been fired nine years earlier, it was struggling to survive as a mainstream computer manufacturer.

Read more

Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Trending Articles

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Rupert Lowe axes pensions triple lock and pledges tax cuts in economic plan

  • As it happened: Stocks rise as oil fluctuates after Red Sea attack; US-Iran deal ‘being circulated’

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • WPP slashes jobs as revenue continues to fall

More from Morning Wire

  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire
  • Leeds NHS Innovation to Accelerate Global Adoption of AI-enabled Pathology for Cancer Diagnostics Through Epredia Partnership

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Iksuda receives US FDA IND clearance for IKS04

    Business Wire
  • Apple sues Open AI accusing them of stealing ‘trade secrets’

    Tech
  • Ignore Palantir’s political opponents and look at the data: this technology helps patients

    Opinion
    NHS logo on a white surface with visible water droplets, blue and white branding
  • Mary Kay’s Pink Changing Lives® Program Turns Purpose Into Measurable Impact for Women Around the World

    Business Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook